Bender Jeremy 4

What Happened
Jeremy Bender, CEO of Day One Biopharmaceuticals (DAWN), received equity awards on January 30, 2026: 355,000 derivative option awards and 237,000 restricted stock units (RSUs). Both grants are reported at a $0.00 price in the filing (transaction code A for award). These were grants by the company as compensation — not open‑market purchases or sales — and do not represent immediate cash proceeds or share sales.

Key Details

• Transaction date: 2026-01-30; transaction type: Award/Grant (code A); reported price: $0.00 for both items.
• Awards: 355,000 options (derivative award) and 237,000 RSUs (each RSU = right to one share on settlement).
• Vesting for options: 1/48th of the total vests monthly beginning February 28, 2026 (i.e., a 4‑year monthly schedule), contingent on continued service.
• Vesting for RSUs: 1/16th vests quarterly on Feb 15, May 15, Aug 15 and Nov 15 (i.e., a 4‑year quarterly schedule), contingent on continued service.
• RSU expiration: RSUs do not expire; they either vest or are canceled prior to vesting.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Timeliness: Filing appears timely (report and filing date both 2026-01-30).

Context
These grants are standard compensation awards that vest over time and become company stock only as they vest (options require exercise per plan terms and RSUs convert to shares upon settlement). Such awards are routine for executives and reflect future‑service incentives rather than an immediate market buy or sell.